Diabetic Foot Ulcer Biologics Market To Reach $3.11 Billion By 2030

Diabetic Foot Ulcer Biologics Market Growth & Trends

The global diabetic foot ulcer biologics market size is anticipated to reach USD 3.11 billion by 2030 and is projected to grow at a CAGR of 7.9% from 2025 to 2030, based on a new report by Grand View Research, Inc. This growth can be attributed to the growing competition among the market participants, rising research activities, the increasing number of clinical trials and studies along with increasing geriatric population. Moreover, the rising focus of industry players on expanding their presence is anticipated to propel market growth in the coming years.

For instance, a study from the National Library of Medicine in August 2022 reported that the risk of DFU increases with age. This correlation is closely linked to the longer duration of diabetes, the cumulative effects of hyperglycemia, and a higher prevalence of micro- and macrovascular complications. Therefore, the increasing prevalence of the geriatric population is expected to lead to a rise in diabetic foot ulcers. According to data published by the WHO in October 2024, the number of older people is estimated to increase significantly in the coming years. Below are some projections given by the WHO:

• By 2030, 1 in 6 people worldwide will be aged 60 or older, with the population in this age group growing from 1 billion in 2020 to 1.4 billion.

• By 2050, the worldwide population of individuals aged 60 and above is estimated to double, reaching 2.1 billion.

• The number of people aged 80 or older is expected to triple from 2020 to 2050, reaching 426 million.

The increasing number of clinical trials is also expected to drive the market during the forecast period, attracting several companies to develop innovative treatments for diabetic foot ulcers. Various industry participants are actively engaged in clinical studies to bring novel biologics in the industry. For instance, in January 2025, RION, a clinical-stage regenerative medicine company, announced the completion of patient enrollment for its Phase 2 clinical trial of the Purified Exosome Product (PEP) in treating diabetic foot ulcers (DFUs). This prospective, multicenter, open-label study enrolled 59 patients across the U.S. It aims to assess the safety and efficacy of PEP when applied topically alongside standard wound care. PEP is a proprietary, lyophilized powder derived from human platelets that contains stabilized regenerative exosomes. These exosomes are engineered to enhance the body’s natural healing processes by promoting cellular growth and reducing inflammation while also protecting vulnerable tissues-crucial elements for successful wound healing.

 Request a free sample copy or view report summary: Diabetic Foot Ulcer Biologics Market Report

Diabetic Foot Ulcer Biologics Market Report Highlights

• Based on product, the skin substitutes segment dominated the global diabetic foot ulcer biologics market in 2024. On the other hand, the tissue-engineered products segment is anticipated to grow at the fastest in the coming years.

• Based on indication, the neuro-ischemic ulcers segment held the largest revenue share of around 53.17% in the market in 2024. In contrast, the ischemic diabetic foot ulcer segment is expected to grow the fastest CAGR over the forecast period.

• Based on end use, the hospital segment dominated the market and accounted for a revenue share of 51.52% in 2024. On the other hand, ambulatory surgical centers segment is expected to grow the fastest over the forecast period.

Diabetic Foot Ulcer Biologics Market Segmentation

Grand View Research has segmented the global diabetic foot ulcer biologics market based on product, indication, end-use, and region:

Diabetic Foot Ulcer Biologics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Skin Substitutes

  • Biological

  • Synthetic

  • Bio-Synthetic

• Growth Factors

• Tissue-Engineered Products

Diabetic Foot Ulcer Biologics Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Neuro-ischemic Ulcers

• Neuropathic Diabetic Foot Ulcer

• Ischemic Diabetic Foot Ulcer

Diabetic Foot Ulcer Biologics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Clinics

• Ambulatory Surgical Centers (ASCs)

• Long-Term Care Settings

• Others

Diabetic Foot Ulcer Biologics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Diabetic Foot Ulcer Biologics Market

• Organogenesis Holdings Inc.

• Tissue Regenix

• BioTissue

• Integra LifeSciences

• MIMEDX Group, Inc.

• Convatec Inc.

• Coloplast Group (Kerecis)

• Biocomposites

• Smith+Nephew, Inc.

• Stedical Scientific, Inc.

• Zimmer Biomet

• GUNZE LIMITED